Skip to content
Screener

Geron GERN Current ratio

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.5×+0.3×
Incyte logo
IncyteINCY
4.6×+1.7×
Immunome logo
ImmunomeIMNM
21.7×+11.2×
Exelixis logo
ExelixisEXEL
3.5×-0.1×
CTO
Citius Oncology, Inc.CTOR
0.5×+0.1×
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
-1.3×

Other financials

Income statement

See full
Revenue$57.5M+17.2%
Operating income-$12.5M-0.3%
Net income-$16.7M-1.9%
EPS (diluted)-$0.020.0%

Balance sheet

See full
Cash & equivalents$64.5M-18.9%
Total debt$134.1M-0.3%
Total equity$218.6M-15.8%
Total assets$519.0M-6.5%

Cash flow

See full
Operating cash flow-$15.8M+42.3%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$1.01B+13.8%
Enterprise value$1.08B+14.5%
P/S4.9×-180×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-28.3%-2.3pp
Debt / equity0.6×+0.1×

Where this comes from

Calculated from Geron’s reported figures.

Based on the most recent quarter.

The source filing: Geron’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:41 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000886744-26-000037

FAQ

What is Geron's current ratio?
Geron (GERN) reported current ratio of 6.9× in Q2 2026.
How has Geron's current ratio changed year-over-year?
Geron's current ratio decreased by 12.1% year-over-year, from 7.9× to 6.9×.
What is the long-term trend for Geron's current ratio?
Over 5 years (2020 to 2025), Geron's current ratio has grown at a -6.3% compound annual growth rate (CAGR), from 6.5× to 4.7×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.

Ask your AI about Geron's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude